Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
SKYE
$0.753
$
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Next Earnings
2026-02-25
Beta
2.817
Average Volume
Market Cap
Last Dividend
CIK
0001516551
ISIN
US83086J2006
CUSIP
83086J101
CEO
Punit S. Dhillon
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
16
IPO Date
2014-11-26
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of “Moderate Buy” from Analysts | Shares of Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, four have assigned a buy recommendation | Defense World | 2026-02-13 02:08:48 |
| Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year | Skye Bioscience, Inc. (NASDAQ: SKYE) on Monday shared interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond proof-of-concept study of nimacimab. | Benzinga | 2026-02-02 13:26:02 |
| Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide | 22.3% total weight loss at 52 weeks with nimacimab (200 mg dose) + semaglutide (2.4 mg) combination — no plateau observed, suggesting potential for further efficacy beyond one year and at higher nimacimab doses Weight regain during treatment interruption reduced by over 50% — nimacimab + semaglutide cohort regained only 17.8% of lost weight vs. 37.3% for semaglutide alone during 13-week off-therapy follow-up, demonstrating durability advantage Strong safety and tolerability profile maintained — no serious adverse events or adverse events of special interest reported during the 52-week extension period SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced interim 52-week data from the combination therapy arms in the extension phase of the Phase 2a CBeyond™ proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody. | GlobeNewsWire | 2026-02-02 07:00:00 |
| Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference | SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled "Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model" at Keystone's conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects. Skye's presentation addressed the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody: Can nimacimab enhance optimal and suboptimal doses of incretin agonists? | GlobeNewsWire | 2026-01-29 07:00:00 |
| Skye Bioscience to Present Poster at Keystone Obesity Conference | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a poster at Keystone's conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects. Skye's presentation addresses the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody: Can nimacimab enhance optimal and suboptimal doses of incretin agonists? | GlobeNewsWire | 2026-01-21 07:00:00 |
| Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm | NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Skye Bioscience, Inc. (NASDAQ: SKYE) breached their fiduciary duties to shareholders. | GlobeNewsWire | 2026-01-20 11:19:00 |
| Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Moderate Buy” from Brokerages | Shares of Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, four have issued a buy | Defense World | 2026-01-19 02:44:50 |
| Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE | LOS ANGELES, Jan. 19, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. | PRNewsWire | 2026-01-19 02:13:00 |
| SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm | LOS ANGELES, Jan. 19, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 4, 2024 and October 3, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before January 16, 2026. | PRNewsWire | 2026-01-19 02:04:00 |
| SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit | NEW YORK, Jan. 16, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline. So what: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. | PRNewsWire | 2026-01-16 15:01:00 |
| INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience | Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. ("Skye" or the "Company") (NASDAQ: SKYE) and reminds investors of the January 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. | Newsfile Corp | 2026-01-16 10:31:00 |
| SKYE DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SKYE | New York, New York--(Newsfile Corp. - January 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. | Newsfile Corp | 2026-01-15 15:17:00 |
| SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE | NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline. | GlobeNewsWire | 2026-01-15 14:58:00 |
| SKYE BIOSCIENCE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th | Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options | GlobeNewsWire | 2026-01-15 12:05:00 |
| SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm | LOS ANGELES, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 16, 2026. | GlobeNewsWire | 2026-01-15 11:11:00 |
| DEADLINE TOMORROW: Berger Montague Advises Skye Bioscience, Inc. (SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026 | Philadelphia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company") on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the "Class Period"), inclusive. Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than January 16, 2026, seek to be appointed as a lead plaintiff representative of the class. | Newsfile Corp | 2026-01-15 09:16:00 |
| Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm | NEW YORK, Jan. 15, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. | PRNewsWire | 2026-01-15 09:00:00 |
| Shareholders that lost money on Skye Bioscience, Inc. (SKYE) should contact The Gross Law Firm about pending Class Action - SKYE | NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). | GlobeNewsWire | 2026-01-14 19:00:00 |
| Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors | LOS ANGELES, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Skye Bioscience, Inc., (“Skye” or the “Company”) (NASDAQ: SKYE) investors of a class action on behalf of investors that bought securities between November 4, 2024 and October 3, 2025, inclusive (the “Class Period”). Skye investors have until January 16, 2026 to file a lead plaintiff motion. | GlobeNewsWire | 2026-01-14 13:33:00 |
| INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience | Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options | GlobeNewsWire | 2026-01-14 10:31:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-20 | 2026-02-20 | View Filing |
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 4 | 2026-02-09 | 2026-02-09 | View Filing |
| 8-K | 2026-02-02 | 2026-02-02 | View Filing |
| 8-K | 2025-12-23 | 2025-12-23 | View Filing |
| SC 13D/A | 2025-12-16 | 2025-12-16 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| 10-Q | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-10-06 | 2025-10-06 | View Filing |
| 4 | 2025-08-22 | 2025-08-22 | View Filing |
| 4 | 2025-08-22 | 2025-08-22 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-06-11 | 2025-06-11 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| 3 | 2025-04-25 | 2025-04-25 | View Filing |
| ARS | 2025-04-25 | 2025-04-25 | View Filing |
| DEFA14A | 2025-04-25 | 2025-04-25 | View Filing |
| DEF 14A | 2025-04-25 | 2025-04-25 | View Filing |
| SC 13G/A | 2025-04-10 | 2025-04-10 | View Filing |
| S-8 | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| 10-K | 2025-03-20 | 2025-03-20 | View Filing |
| 4/A | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 4 | 2025-02-26 | 2025-02-26 | View Filing |
| 8-K | 2025-02-26 | 2025-02-26 | View Filing |
| UPLOAD | 2025-02-05 | 2025-02-05 | View Filing |
| CORRESP | 2024-12-23 | 2024-12-23 | View Filing |
| SC 13D/A | 2024-12-19 | 2024-12-19 | View Filing |
| UPLOAD | 2024-12-16 | 2024-12-16 | View Filing |
| 4 | 2024-11-20 | 2024-11-20 | View Filing |
| 4 | 2024-11-19 | 2024-11-19 | View Filing |
| 4 | 2024-11-19 | 2024-11-19 | View Filing |
| 4 | 2024-11-19 | 2024-11-19 | View Filing |
| 144 | 2024-11-15 | 2024-11-15 | View Filing |
| 144 | 2024-11-15 | 2024-11-15 | View Filing |
| 144 | 2024-11-15 | 2024-11-15 | View Filing |
| 144 | 2024-11-15 | 2024-11-15 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| S-8 | 2024-11-07 | 2024-11-07 | View Filing |
| 10-Q | 2024-11-07 | 2024-11-07 | View Filing |
| 8-K | 2024-11-07 | 2024-11-07 | View Filing |
| 4 | 2024-10-30 | 2024-10-30 | View Filing |
| 4 | 2024-10-30 | 2024-10-30 | View Filing |
| 4 | 2024-10-30 | 2024-10-30 | View Filing |
| 4 | 2024-10-30 | 2024-10-30 | View Filing |
| 4 | 2024-10-30 | 2024-10-30 | View Filing |
| 4 | 2024-10-30 | 2024-10-30 | View Filing |
| 4 | 2024-10-30 | 2024-10-30 | View Filing |
| 4 | 2024-10-30 | 2024-10-30 | View Filing |
| 8-K | 2024-10-29 | 2024-10-29 | View Filing |
| 8-K | 2024-10-24 | 2024-10-24 | View Filing |
| DEF 14A | 2024-09-23 | 2024-09-23 | View Filing |
| 4 | 2024-09-13 | 2024-09-13 | View Filing |
| 4 | 2024-09-13 | 2024-09-13 | View Filing |
| PRE 14A | 2024-09-13 | 2024-09-13 | View Filing |
| 4 | 2024-09-04 | 2024-09-04 | View Filing |
| 8-K | 2024-09-04 | 2024-09-04 | View Filing |
| 3 | 2024-09-04 | 2024-09-04 | View Filing |
| 4 | 2024-08-27 | 2024-08-27 | View Filing |
| SC 13G | 2024-08-14 | 2024-08-14 | View Filing |
| S-8 | 2024-08-12 | 2024-08-09 | View Filing |
| S-8 | 2024-08-09 | 2024-08-09 | View Filing |
| 10-Q | 2024-08-09 | 2024-08-09 | View Filing |
| 4 | 2024-07-05 | 2024-07-05 | View Filing |
| 3 | 2024-07-05 | 2024-07-05 | View Filing |
| 8-K | 2024-07-03 | 2024-07-03 | View Filing |
| 8-K | 2024-06-10 | 2024-06-10 | View Filing |
| EFFECT | 2024-05-20 | 2024-05-20 | View Filing |
| EFFECT | 2024-05-20 | 2024-05-20 | View Filing |
| 424B3 | 2024-05-17 | 2024-05-17 | View Filing |
| CORRESP | 2024-05-15 | 2024-05-15 | View Filing |
| CORRESP | 2024-05-15 | 2024-05-15 | View Filing |
| CORRESP | 2024-05-15 | 2024-05-15 | View Filing |
| CORRESP | 2024-05-15 | 2024-05-15 | View Filing |
| UPLOAD | 2024-05-14 | 2024-05-14 | View Filing |
| UPLOAD | 2024-05-14 | 2024-05-14 | View Filing |
| S-3 | 2024-05-10 | 2024-05-10 | View Filing |
| S-3 | 2024-05-10 | 2024-05-10 | View Filing |
| 10-Q | 2024-05-10 | 2024-05-10 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|